Table 1.
Baseline Demographics and Clinical Characteristics of 53 Patients on Trial
| Characteristic | Dabrafenib alone (N = 26), n (%) | Dabrafenib + trametinib (N = 27), n (%) |
|---|---|---|
| Median age in years (range) | 60 (37–84) | 65 (43–84) |
| Female | 8 (31) | 7 (26) |
| Race | ||
| White | 25 (96) | 24 (89) |
| African American | 0 (0) | 2 (7) |
| Asian | 1 (4) | 1 (4) |
| ECOG performance status | ||
| 0 or 1 | 23 (88) | 26 (96) |
| 3 (12) | 1 (4) | |
| Histologic subtype | ||
| Papillary | 25 (96) | 24 (89) |
| Follicular | 1 (4) | 0 (0) |
| Hurthle cell | 0 (0) | 2 (8) |
| Poorly DTC | 0 (0) | 1 (4) |
| BRAF mutation | ||
| V600E | 25 (96) | 27 (100) |
| K601E | 1 (4) | 0 (0) |
| Site of metastases | ||
| Lung | 22 (85) | 23 (85) |
| Lymph node | 10 (38) | 15 (56) |
| Bone | 7 (27) | 3 (11) |
| Liver | 2 (8) | 2 (7) |
| Other | 4 (15) | 6 (22) |
| Prior therapy | ||
| Surgery | 26 (100) | 27 (100) |
| Radiotherapy | 16 (62) | 10 (37) |
| Radioactive iodine | 26 (100) | 27 (100) |
| Chemotherapy | 0 (0) | 1 (2) |
| Prior tyrosine kinase inhibitor# (up to 3 allowed) | 6 (23) | 5 (19) |
Dabrafenib single agent and dabrafenib + trametinib upfront combination. Crossover patients not included here.
DTC, differentiated thyroid cancer.